Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Fineline Cube Jan 22, 2026
Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Fineline Cube Jan 22, 2026
Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Fineline Cube Jan 22, 2026
Company Deals

GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection

Fineline Cube Jan 22, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

Henlius Biotech’s Biosimilar Herceptin Approved by Health Canada for Breast and Gastric Cancer Treatments

Fineline Cube Aug 23, 2024

Shanghai Henlius Biotech Inc., a leading biopharmaceutical company based in China and listed on the...

Company Drug

Jiangsu Simcere Pharmaceutical Gets NMPA Green Light for SIM0508 Clinical Trial in Advanced Solid Tumors

Fineline Cube Aug 23, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2096),...

Company Drug

Mabwell Bioscience Receives Approval for Phase III Trial of 9MW2821 in Cervical Cancer from China’s CDE

Fineline Cube Aug 23, 2024

Mabwell (Shanghai) Bioscience Co., Ltd, a biopharmaceutical company listed in China (SHA: 688062), has received...

Company Deals

ImmuneOnco Receives USD 10 Million Upfront Payment from Instil Bio Subsidiary for Licensing Deal

Fineline Cube Aug 23, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has received a USD 10 million upfront payment...

Company Drug

Gene Cradle Initiates First Regulatory Gene Therapy Study in China for Late-Onset Pompe Disease

Fineline Cube Aug 23, 2024

Gene Cradle, a Beijing-based gene therapy specialist, has achieved a milestone by administering its GC301...

Company Drug

Phase I Success for Shandong Xinhua’s OAB-14, Advancing to Phase IIa in Alzheimer’s Therapy

Fineline Cube Aug 23, 2024

Shandong Xinhua Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Shenzhen (SHE: 000756), has...

Company

Jiangsu Hengrui Pharmaceuticals Co., Ltd Announces Resignations of Two Deputy General Managers

Fineline Cube Aug 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China and listed on...

Company Drug

Hunan Warrant Pharmaceutical’s ZG-002 Receives NMPA Approval for Clinical Trials in Plaque Psoriasis

Fineline Cube Aug 23, 2024

Hunan Warrant Pharmaceutical Co., Ltd, a pharmaceutical company based in China and listed on the...

Company Medical Device

Allgens Medical Technology’s BonGold Receives Marketing Approval from Malaysia’s MDA

Fineline Cube Aug 23, 2024

Allgens Medical Technology Co., Ltd, a Beijing-based innovator in regenerative medicine materials and implantable devices...

Company Deals

Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights

Fineline Cube Aug 23, 2024

Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Deals

Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases

Fineline Cube Aug 23, 2024

Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital...

Company Drug

UK MHRA Approves Eisai and Biogen’s Alzheimer’s Drug Leqembi, Despite NICE Reimbursement Rejection

Fineline Cube Aug 23, 2024

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Leqembi (lecanemab),...

Company

Ascentage Pharma’s 2024 Interim Results Highlight 477% YOY Revenue Growth and First-Ever Profitability

Fineline Cube Aug 23, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced its 2024 interim...

Company

3SBio Inc. Reports 16% YOY Revenue Growth in 2024 Interim Financial Report, Highlighting Biomedicine Segment Strength

Fineline Cube Aug 23, 2024

3SBio Inc., a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1530),...

Company

Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy

Fineline Cube Aug 23, 2024

Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong...

Company Drug

Everest Medicines Launches Trial for Personalized mRNA Cancer Vaccine EVM16 in Solid Tumors

Fineline Cube Aug 23, 2024

Everest Medicines, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Drug

Regeneron’s Linvoseltamab Faces FDA Complete Response Letter, Awaiting Reinspection of Manufacturer

Fineline Cube Aug 23, 2024

Regeneron Pharmaceuticals Inc., a leading biopharmaceutical company based in the US and listed on the...

Company Legal / IP

Astellas Pharma Employee in China Formally Indicted on Espionage Suspicion

Fineline Cube Aug 23, 2024

Astellas Pharma Inc., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange (TYO: 4503),...

Company Drug

CK Life Sciences’ Halneuron Receives FDA Fast-Track Designation for Chemotherapy-Induced Neuropathic Pain

Fineline Cube Aug 23, 2024

CK Life Sciences (HKG: 0775), a biopharmaceutical company headquartered in China, has received fast-track designation...

Company Deals

GSC to Distribute Hecin’s Innovative PCR and RT-PCR Solutions in Middle Eastern Markets

Fineline Cube Aug 23, 2024

Gulf Scientific Corporation (GSC), a prominent life sciences service provider headquartered in Dubai, United Arab...

Posts pagination

1 … 255 256 257 … 612

Recent updates

  • BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform
  • Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery
  • Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform
  • Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials
  • GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Others

Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.